Otto Yang posted on FB earlier today: “Unfortunately, another one bites the dust. In my mind this raises some concerns about tocilizumab, since sarilumab and tocilizumab work the same way.
This is an IL6 receptor blocker, an antibody that stops a major part of the immune system. The idea/hope is that it could reduce lung inflammation in COVID-19. Unfortunately this study was stopped because it wasn't working, and also some patients were having very severe side effects.” and linked to: https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30-00
News 
Market Data 
Discover 
